

Ordering Physician or Delegate to Complete

Test Selected

DetermaRx™ EGFR (tumor tissue analysis - Exon 18-21)

DetermaRx Intended Use: Improving the quality of post-surgical treatment decisions by identifying patients at highest risk of 5-year mortality, and therefore the most likely to benefit from adjuvant chemotherapy, in stage IA, IB and IIA (8th edition) non-squamous non-small cell lung cancer patients whose tumors have been fully resected and are candidates for chemotherapy.

Ordering Physician Information

Physician Name _____
 Organization Name _____
 NPI Number _____
 Street Address _____
 City _____ State _____
 Postal Code _____ Country _____
 Phone _____ Fax _____
 Email Address (For online report access) _____

Report Delivery Encrypted Email Secured Fax

You are authorizing the electronic delivery of test results by Oncocyte in accordance with the Health Insurance Portability and Accountability Act (HIPAA) and the rules reflected in the HITECH Act.

Patient Information

Last Name _____ Suffix _____
 First Name _____ Middle Initial _____
 Sex F M Undisclosed Date of Birth (DOB mm/dd/yyyy) _____
 Last 4-digits of SSN _____ Medical Record # _____
 Street Address _____
 City _____ State _____
 Postal Code _____ Country _____
 Phone _____
 Email Address (For Invoicing) _____
 Patient Diagnosis (ICD-10 Codes) _____
 Hospital Status at Time of Specimen Collection:
 In-Office Procedure Hospital Outpatient Hospital Inpatient (>24 hour)
 Discharge Date (mm/dd/yyyy) _____ Not Yet Discharged

Pathology Laboratory Information

Oncocyte to request specimen from Pathology Ordering Physician to request specimen from Pathology
 Contact Name _____
 Organization Name _____
 Street Address _____
 City _____ State _____
 Postal Code _____ Country _____
 Phone _____ Fax _____

Ordering Physician Signatures & Attestations

I, the undersigned, attest that I ordered the DetermaRx test and/or the EGFR test for my eligible patient, and this order is appropriately documented in the Patient Medical record. The test(s) is/are medically necessary and reasonable to provide information to allow me to personalize treatment for my patient's medical condition. This patient has a non-squamous NSCLC with a tumor size < 5cm, and there are no positive lymph nodes (i.e. American Joint Committee on Cancer Eighth Edition Stages I and IIA); the patient is sufficiently healthy to tolerate chemotherapy, and adjuvant platinum containing chemotherapy is being considered for the patient. I have provided Oncocyte with my patient's current insurance information, and I understand that Oncocyte will be billing the patient's insurance company and accepting assignment on this claim. The patient and/or their legal guardian has been informed of the benefits, risks, and limitations of the laboratory test(s) and requested and consented for this test to be performed.

X

Treating Physician Signature (or Authorized Delegate) _____ Date (mm/dd/yyyy) _____

*Delegate has the authorization to sign supporting forms and documents on behalf of the Treating Physician for Oncocyte orders.

Billing Information

Billing Type: Medicare Medicaid/IPA Commercial Self-Pay

Primary Insurance Name _____

Plan Name _____

Insurance ID# _____ Group# _____

Patient relationship with subscriber Self Spouse Dependent

Subscriber Name (if not patient) _____

Address _____

Sex F M Undisclosed Date of Birth (DOB mm/dd/yyyy) _____

Secondary Insurance Name _____

Plan Name _____

Insurance ID# _____ Group# _____

Patient relationship with subscriber Self Spouse Dependent

Subscriber Name (if not patient) _____

Address _____

Sex F M Undisclosed Date of Birth (DOB mm/dd/yyyy) _____

Attach a copy of both sides of primary/secondary insurance cards.

If Patient needs financial assistance, call 1.844.662.6298 or visit Oncocyte.com to obtain the Financial Assistance Form.

Specimen Information

IASLC TNM Staging T _____ N _____ M _____
 (when available)

IASLC Overall Stage IA IB IIA
 (select one)

FFPE Block ID (Case ID) _____

Specimen Collection Date (mm/dd/yyyy) _____

Number of primary non-squamous NSCLC lesions to be tested _____

Pathology to Complete

Review and update your contact information above and fill in the sample information. Select a surgical FFPE specimen (not a biopsy) with a tumor area greater than 25% of the block's total tissue area, without regard to cell density. The FFPE specimen must be non-squamous NSCLC in a stage IA, IB, or IIA.

Specimen Type Submitted*

Block Please return specimen to the above address if submitting block
 Slides # of slides sent

FFPE Block(s) Cross-Section ID (Case Affix) _____

Date Block(s) Removed from Storage: (mm/dd/yyyy) _____

Completed by X _____

Date (mm/dd/yyyy) _____